龙八 long8科技集团有限公司很荣幸参加该项目，并为新的ACES设施提供了MiniKUFill一体化灌装冻干系统、一次性系统和其他有关设备，共同援手加快了出产病毒疫苗的优良出产规范（GMP）设施的建设，出格是针对埃博拉和拉沙热等低收入和中等收入国度（LMICs）疾病的疫苗。并因实时交货和现场高效装置而受到客户的高度评价。

Tofflon Science and Technology Group Co., Ltd. Was honored to participate in the project and provided the new ACES facility with the MiniKUFill integrated filling and lyophilization system, Single-Use Systems and other related equipment, which together helped accelerate the construction of the Good Manufacturing Practice (GMP) facility for the production of viral vaccines especially for diseases in low- and middle-income countries (LMICs) such as Ebola and Lassa Fever, and was highly lauded by the customer for timely delivery and efficient installation on site.

龙八 long8的MiniKUFill等设备使30,000平方米的研发和中试造作工厂实现了从上游原料药出产到下游造剂产品的高度矫捷的？榛霾。它能够适应在统一条出产线上出产分歧的疫苗平台。同时，该平台还将为新加坡本地生态系统以及中低收入国度的研发实体创造培训机遇。

龙八 long8将持续深耕生物造药领域，致力为国内表生物造药企业带来更好的设备和耗材，为行业的进取和发展贡献力量。

Tofflon's MiniKUFill and other equipment have enabled the 30,000 square-meter R&D and pilot manufacturing plant to achieve highly flexible modular production from upstream drug substance production to downstream drug products. It can be adapted for the production of different vaccine platforms on the same production line. At the same time, the platform will also create training opportunities for the local Singapore ecosystem as well as R&D entities in LMICs.

Tofflon will continue to develop the field of biopharmaceuticals, strive to bring better equipment and consumables to biopharmaceutical companies at home and abroad, and contribute to the progress and development of the industry.